Skip to main navigation Skip to search Skip to main content

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma

  • Aurel Prosz
  • , Haohui Duan
  • , Viktoria Tisza
  • , Pranshu Sahgal
  • , Sabine Topka
  • , Gregory T. Klus
  • , Judit Börcsök
  • , Zsofia Sztupinszki
  • , Timothy Hanlon
  • , Miklos Diossy
  • , Laura Vizkeleti
  • , Dag Rune Stormoen
  • , Istvan Csabai
  • , Helle Pappot
  • , Joseph Vijai
  • , Kenneth Offit
  • , Thomas Ried
  • , Nilay Sethi
  • , Kent W. Mouw
  • , Sandor Spisak
  • Shailja Pathania, Zoltan Szallasi
  • Danish Cancer Institute
  • University of Massachusetts Boston
  • Boston Children's Hospital
  • Research Centre for Natural Sciences
  • Dana-Farber Cancer Institute
  • Harvard University
  • Broad Institute
  • Memorial Sloan-Kettering Cancer Center
  • National Institutes of Health
  • University of Copenhagen
  • Semmelweis University
  • Eotvos Lorand University
  • Cornell University
  • Brigham and Women’s Hospital

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number20567
JournalScientific Reports
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus Subject Areas

  • General

Fingerprint

Dive into the research topics of 'Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Cite this